-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hairy cell leukemia (HCL) is a rare inert B-cell proliferative malignant hematopathy that is commonly associated
The study was an open-label, Phase 2 clinical trial that enrolled patients with positive HCL of BRAF V600E mutations who did not respond to first-line therapy with purine analogues or who relapsed after previous treatment with
Patients with
The most common treatment-related adverse effects were fever (58.
In summary, dalafinil plus trametinib demonstrated a durable response and controlled safety in patients with HCL positive for relapsed/refractory BRAF V600E mutations, consistent with what had previously been observed in patients with other indications, and could be considered as a treatment option
Original Source:
Kreitman Robert J,Moreau Philippe,Ravandi Farhad et al.